Urea and guanidine hydrochloride solubilize aggregates by weakening the noncovalent forces that hold misfolded proteins together. Their denaturing action disrupts hydrophobic interactions and hydrogen bonding, allowing the target polypeptide to become dispersed rather than remain in a dense particle. This chemical unfolding step exposes the protein for subsequent purification and controlled refolding.
Reducing agents target incorrect disulfide bonds that can stabilize protein aggregates. By disrupting these covalent linkages, they complement the action of denaturants, which primarily weaken hydrophobic interactions and hydrogen bonding. Including reduction in the solubilization strategy can therefore help release the target protein from structurally incorrect assemblies before refolding conditions are introduced.
Controlled denaturant removal gives an unfolded protein an opportunity to regain a functional structure while limiting unwanted aggregation. If the transition from strongly denaturing conditions is not properly managed, protein molecules may associate again instead of refolding productively. Optimization is therefore needed to balance aggregate suppression with preservation of the target protein's activity.
The aggregated recombinant protein is first exposed to a strong denaturant, often with a reducing agent, to produce a soluble protein preparation. The denaturant is then removed or diluted under controlled conditions. This transition supports refolding, after which the protein can be made available for purification and evaluated for retained activity.
Optimization centers on the denaturing environment and the way it is changed afterward. The selected strong denaturant must sufficiently disrupt the interactions stabilizing the aggregate, while its removal or dilution must limit renewed aggregation. Reducing conditions may also need consideration when incorrect disulfide bonds contribute to the aggregate, with the final goal of preserving protein activity.
This approach is useful when recombinant production yields a target protein in an aggregated, insoluble form rather than a readily usable preparation. It supports recovery of enzymes, antibodies, and other valuable proteins for purification, structural studies, diagnostics, and biotechnology. Its value lies in linking aggregate dissolution with a subsequent opportunity to restore a functional protein structure.